CX-2009, a CD166-directed probody drug conjugate (PDC): Results from the first-in-human study in patients (Pts) with advanced cancer including breast cancer (BC).
Document Type
Article
Publication Date
5-25-2020
Publication Title
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Clinical Institute
Cancer
Department
Oncology
Department
Earle A. Chiles Research Institute
Recommended Citation
Boni, Valentina; Burris III, Howard A.; Liu, Joyce F.; Spira, Alexandra I.; Arkenau, Hendrik-Tobias; Fidler, Mary J.; Rosen, Lee S.; Sweis, Randy F.; Uboha, Nataliya Volodymyrivna; Sanborn, Rachel E; O'Neil, Bert; Harding, James J.; LoRusso, Patricia; Weise, Amy M.; Garcia-Corbacho, Javier; Victoria, Ivan; Frye, John W.; Li, Rachel; Stroh, Mark; and Meric-Bernstam, Funda, "CX-2009, a CD166-directed probody drug conjugate (PDC): Results from the first-in-human study in patients (Pts) with advanced cancer including breast cancer (BC)." (2020). Articles, Abstracts, and Reports. 3765.
https://digitalcommons.providence.org/publications/3765
